Skip to main content
Premium Trial:

Request an Annual Quote

Celera Grants Bayer Cancer Rx License; Retains Companions Dx Rights

NEW YORK (GenomeWeb News) – Celera today said that it has licensed exclusive worldwide rights to Bayer Schering Pharma for five cancer-related drug targets and associated in vivo diagnostic imaging.

The Alameda, Calif.-based molecular diagnostics firm said that it will retain in vitro diagnostic rights and will be able to develop and sell companion diagnostics specific to therapeutic compounds developed by Bayer under the deal.

Celera said that the therapeutic targets are over-expressed on the surface of several different tumor cell types and were identified using its proteomics discovery platform.

Bayer Schering Pharma will pay Celera a one-time fee for the exclusive rights to the five targets. It also will make additional milestone payments based on development and commercialization goals, and it also will pay royalties to Celera based on product sales.

Steve Rubin, vice president of proteomic research at Celera, said that the deal allows Celera "the flexibility to advance part of our broad pipeline of validated targets for additional future value."

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.